Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned a $80.00 price objective by equities researchers at SunTrust Banks, Inc. in a report released on Sunday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks, Inc.’s target price would indicate a potential upside of 34.14% from the stock’s previous close.

Other research analysts have also issued reports about the company. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $83.00 price target (up from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. J P Morgan Chase & Co reiterated a “buy” rating and set a $76.00 price target on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Royal Bank Of Canada assumed coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price target for the company. Leerink Swann upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $50.00 to $80.00 in a report on Wednesday, August 2nd. Finally, Janney Montgomery Scott reiterated a “hold” rating on shares of Agios Pharmaceuticals in a report on Tuesday, August 1st. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $75.70.

Agios Pharmaceuticals (AGIO) opened at $59.64 on Friday. Agios Pharmaceuticals has a 1-year low of $39.24 and a 1-year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The company had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same period in the previous year, the company earned ($1.63) earnings per share. The company’s quarterly revenue was up 26.4% compared to the same quarter last year. equities analysts predict that Agios Pharmaceuticals will post -6.59 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Agios Pharmaceuticals, Inc. (AGIO) PT Set at $80.00 by SunTrust Banks, Inc.” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://theolympiareport.com/2017/11/20/agios-pharmaceuticals-inc-agio-pt-set-at-80-00-by-suntrust-banks-inc.html.

In other news, CEO David P. Schenkein sold 6,000 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $62.20, for a total transaction of $373,200.00. Following the sale, the chief executive officer now owns 6,000 shares in the company, valued at $373,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Scott Biller sold 2,146 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $61.99, for a total value of $133,030.54. Following the sale, the insider now owns 8,410 shares in the company, valued at approximately $521,335.90. The disclosure for this sale can be found here. Insiders sold 182,908 shares of company stock worth $12,391,239 over the last quarter. Company insiders own 10.55% of the company’s stock.

Several hedge funds have recently made changes to their positions in AGIO. Teachers Advisors LLC grew its holdings in shares of Agios Pharmaceuticals by 2.3% during the first quarter. Teachers Advisors LLC now owns 30,258 shares of the biopharmaceutical company’s stock worth $1,767,000 after purchasing an additional 666 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Agios Pharmaceuticals by 209.2% during the first quarter. Legal & General Group Plc now owns 10,011 shares of the biopharmaceutical company’s stock worth $585,000 after purchasing an additional 6,773 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Agios Pharmaceuticals by 8,463.5% during the first quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after purchasing an additional 2,141,768 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Agios Pharmaceuticals by 9.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 83,327 shares of the biopharmaceutical company’s stock worth $4,867,000 after purchasing an additional 7,158 shares during the last quarter. Finally, Aperio Group LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter worth $206,000. Institutional investors own 92.64% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.